Navigation Links
Spherix Reports 3rd Quarter Earnings
Date:11/16/2007

BELTSVILLE, Md., Nov. 16 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has reported a loss from continuing operations of $3.1 million ($0.22 per share) and $7.1 million ($0.50 per share) for the three- and nine- months ended September 30, 2007, respectively. These losses exceeded the losses for the corresponding periods of 2006 due to increased expenditures related to the Company's Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes. The Company anticipates the trial to continue through mid-2009. Income from discontinued operations was $8.4 million ($0.59 per share) in the third quarter of 2007, and $8.3 million ($0.59 per share) for the nine months ended September 30, 2007, reflecting the sale of the InfoSpherix subsidiary (see Spherix press release dated August 16, 2007). The Company's total net income was $5.3 million (37 cents per share) and $1.3 million (9 cents per shared), respectively for the three- and nine-months ended September 30, 2007.

Claire L. Kruger, CEO, said, "The sale of InfoSpherix has provided the Company with significant funding that will help us to pursue the Company's strategic interests."

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue from continuing

operations $ 59,000 $ - $ 63,000 $ 3,000

Loss from continuing

operations $(3,122,000) $(981,000) $(7,063,000)$(2,350,000)

Income from discontinued

operations $ 8,416,000 $ 971,000 $ 8,321,000 $ 2,046,000

Net income (loss) $ 5,294,000 $ (10,000 $ 1,258,000 $ (304,000)

Net income (loss) per

share

Continuing operations $ (0.22) $ (0.07 $ (0.50)$ (0.17)

Discontinued

operations $ 0.59 $ 0.07 $ 0.59 $ 0.15

Net income (loss) per

share $ 0.37 $ - $ 0.09 $ (0.02)

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.

Spherix's internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome workshop ... hand surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition of ... a state-of-the-art technology and only 1 of about 3 currently available in the United ...
(Date:5/27/2016)... At present, the Biotech sphere is ... know that volatility is what makes this industry interesting to ... Pharmaceuticals Corp. (NASDAQ: SNTA ), CTI BioPharma Corp. ... LPTN ), and Heat Biologics Inc. (NASDAQ: HTBX ... alerts for these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
(Date:5/25/2016)... San Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... San Diego area and has consistently been rated one of its top attractions. ... over the globe to participate in a unique and intimate team-building experience. , Each ...
Breaking Biology Technology:
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
Breaking Biology News(10 mins):